TNP-470 species, polymer conjugates and use thereof

Details TNP-470 species, polymer conjugates and use thereof TNP-470 species, polymer conjugates and use thereof

2005-09-27

2005-09-27

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S332000

Reexamination Certificate

active

06949584

ABSTRACT:
The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.

REFERENCES:
patent: 5164410 (1992-11-01), Kishimoto et al.
patent: 5166172 (1992-11-01), Kishimoto et al.
patent: 5180735 (1993-01-01), Kishimoto et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 6022888 (2000-02-01), Morishige et al.
patent: 6225478 (2001-05-01), Morishige et al.
patent: 2003/0109671 (2003-06-01), Olson et al.
Folkman, J., Angiogenesis, inHarrison's Textbook of Internal Medicine(eds. Braunwald, E. et al.) 517-530 (McGraw Hill, New York, 2001).
Hanahan, D. et al., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,Cell,86:353-64 (1996).
Volpert, O.V. et al., Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1,Cancer Cell,2:473-483 (2002).
Folkman, J., Tumor angiogenesis,Cancer Medicine(eds. Holland, J. et al.), pp. 132-152 (B. C. Decker Inc., Ontario, Canada, 2000).
Lyden, D. et al., Id1 and Id3 are required for neurogenesis angiogenesis and vascularization of tumour xenografts,Nature,401:670-677 (1999).
Streit, M. et al., Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis,Proc. Natl. Acad. Sci. USA,96:14888-14893 (1999).
Chin, L. et al., Essential role for oncogenic Ras in tumour maintenance,Nature,400:468-472 (1999).
Tabone, M.D. et al., Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?,Clinical Cancer Res.,7:538-543 (2001).
Yao, Y. et al., Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours,Acta Neurochir(Wien), 143:159-66 (2001).
Yuan, A. et al., Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer,J. Clinical Oncology,20:900-910 (2002).
Ingber, D. et al., Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth,Nature,348:555-557 (1990).
Antoine, N. et al., AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1phase of the cell cycle,Cancer Res.,54:2073-2076 (1994).
Kudelka, A.P. et al., Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470,N. Engl. J. Med.,338:991-2 (1998).
Kudelka, A.P. et al., A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix,Clinical Cancer Res.,3:1501-1505 (1997).
Bhargava, P. et al., A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer,Clinical Cancer Res.,5:1989-1995 (1999).
Herbst, R.S. et al., Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer,J. Clinical Oncol.,20:4440-4447 (2002).
Kim, E.S. et al., Angiogenesis inhibitors in lung cancer.Curr. Oncol. Rep.,4:325-333 (2002).
Stadler, W.M. et al., Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma,J. Clinical Oncol.,17:2541-2545 (1999).
Logothetis, C.J. et al., Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer,Clinical Cancer Res.,7:1198-1203 (2001).
Rupnick, M.A. et al., Adipose tissue mass can be regulated through the vasculature,Proc. Natl. Acad. Sci. U S A,99:10730-10735 (2002).
Schoof, D.D. et al., The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro,Int. J. Cancer,55:630-635 (1993).
Nagabuchi, E. et al., TNP-470 antiangiogenic therapy for advanced murine neuroblastoma,J. Pediatric Surg.,32:287-93 (1997).
Rihova, B. et al., Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro,Biomaterials,10:335-342. (1989).
Seymour, L.W. et al., The pharmacokinetics of polymer-bound adriamycin,Biochem. Pharmacol.,39:1125-1131 (1990).
Maeda, H. et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,J. Controlled Release,65:271-284 (2000).
Duncan, R. et al., Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1),Human and Exp. Toxicology,17:93-104 (1998).
Satchi-Fainaro, R., Targeting tumor vasculature: Reality or a dream?.J. Drug Targeting,10:529-533 (2002).
Duncan, R. et al., Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes,Makromol. Chem.,184:1997-2008 (1983).
Foekens, J.A. et al., Prognostic significance of cathepsins B and L in primary human breast cancer.J. Clinical Oncol.,16:1013-1021 (1998).
Gianasi, E. et al., HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo,Eur. J. Cancer,35:994-1002 (1999).
Kusaka, M. et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470),Br. J. Cancer.69:212-216 (1994).
Greene, A.K. et al., Endothelial-directed hepatic regeneration after partial hepatectomy,Ann. Surg.,237:530-535 (2003).
Drixler, T.A. et al., Liver regeneration is an angiogenesis- associated phenomenon,Ann. Surg.,236:703-712 (2002).
Klein, S.A. et al., Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing,J. Surg. Res.,82:268-274 (1999).
Whalen, C.T. et al., Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography-mass spectrometry,J. Chromatographic Sci.,40:214-218 (2002).
Brocchini, S. et al., Polymer-Drug conjugates: drug release from pendent linkers. inEncyclopaedia of controlled release(ed. Mathiovitz, E.) 786-816 (New York: Wiley, 1999).
Duncan, R. et al., Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic,J. Controlled Release,74:135-146 (2001).
Vasey, P.A. et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates, Cancer Research Campaign Phase I/II Committee,Clinical Cancer Res.,5:83-94 (1999).
Seymour, L.W. et al., Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma,Br. J. Cancer,70:636-641 (1994).
Dvorak, H.F. et al., Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.Am. J. Pathology,133:95-109 (1988).
Griffith, E.C. et al., Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin,Chem. and Biol.,4, 461-471 (1997).
Auerbach, R. et al., Angiogenesis assays: problems and pitfalls,Cancer Metastasis Rev.,19:167-172 (2000).
Seymour, L.W. et al., Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.,J. Clinical Oncol.,20:1668-1676 (2002).
Francis, G.E. et al., PEG-modified proteins. inStability of Proteins Pharmaceuticals(Part B) (ed. Ahem Tj, M.M.) 235-263 (Plenum Press, New York, 1992).
Ho, D.H. et al., Clinical pharmacology of polyethylene

Affiliated with

Also associated with

Rating

TNP-470 species, polymer conjugates and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TNP-470 species, polymer conjugates and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNP-470 species, polymer conjugates and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3443375